Earlier this week, Telix Pharmaceuticals reported full-year 2025 sales of US$803.79 million with a small net loss, issued 2026 revenue guidance of US$950–970 million, filed a U.S. shelf registration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results